Elyse Watkins, DHSc, PA-C, DFAAPA
Respiratory syncytial virus (RSV) is a common infection with morbidity and mortality that disproportionately impacts the young and the elderly. Prevention of RSV infection via vaccine-mediated immunity could dramatically reduce morbidity and mortality. The development of an RSV vaccine has proven more difficult for scientists, with efforts to develop an effective vaccine ongoing for nearly 60 years. Recent advancements in vaccine development have resulted in multiple RSV vaccine candidates currently in clinical trials. Multiple vaccines are currently in phase 3 trials with estimated completion dates as early as 2022. Further development of safe and effective disease prevention modalities is needed to reduce the burden RSV places on vulnerable populations and healthcare systems worldwide.
Brier SR. Preventing Respiratory Syncytial Virus in Vulnerable Populations. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2022; 4(3).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.